The 5-year recurrence-free survival rate was 75% in the younger age group and 73% in the older age group. Age may not be a prognostic factor for patients with cervical cancer, according to researchers ...

In the primary efficacy population, the median progression-free survival was not reached in the nivolumab-ipilimumab arm and was 5.9 months in the chemotherapy arm. The combination of nivolumab and ...

Researchers sought to determine the effect of changes in screening guidelines on incidence of breast cancer by stage at diagnosis and surgical management.

Dose-response relationship seen between physical activity and lower rates of cancer progression, all-cause mortality.

At a median follow-up of 12.3 months, 44% of patients with PTCL had an objective response by blinded independent central review in this study, with a median response duration of 11.9 months. Among ...

Prostate cancer treatment guidelines recommend against aggressive therapy for those with a life expectancy of less than 10 years.

Researchers conducted a randomized controlled trial to assess the need for postoperative radioiodine therapy among patients with low-risk thyroid cancer.

Researchers sought to determine whether CNS bridging radiotherapy would improve responses to CAR-T therapy in patients with B-cell lymphomas.

Researchers developed an assay kit for TAT, then conducted a retrospective analysis to determine its ability to predict VTE in patients with cervical cancer.

Grade 3 or 4 adverse events occurred in 96 percent of patients; grade 3 or 4 infections occurred in 64 percent.

The results of this first phase 2 study of belzutifan combined with cabozantinib suggest that dual targeting of HIF-2α and VEGF pathways might be an effective first-line treatment strategy in advanced ...

Researchers found that receipt of neoadjuvant and adjuvant chemotherapy were associated with inadequate ovarian function suppression. Researchers say they have identified several factors that may be ...